Evidence map›Paper›PMID 41649670›Full record

ReviewCell biochemistry and biophysics2026

Neuroinflammation and RAMP1: the Role of the Peripheral and Central Nervous System in Tumor Progression.

Pedro Daniel Moumesso Cavalcante, Jonas Lucas Dias da Silva, Laryssa Rosy Santos Oliveira, Rikelly Barbosa da Silva, Juliana Acioli Costa Lima, Guilherme de Brito Souza, Davi Ramon da Silva Santos, Júllia Victória Nascimento de Abrantes, Mateus Lima de Farias, Sofia Amancio de Almeida Oliveira and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Pedro Daniel Moumesso CavalcanteFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Jonas Lucas Dias da SilvaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Laryssa Rosy Santos OliveiraFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Rikelly Barbosa da SilvaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Juliana Acioli Costa LimaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Guilherme de Brito SouzaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Davi Ramon da Silva SantosFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Júllia Victória Nascimento de AbrantesFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Mateus Lima de FariasFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Sofia Amancio de Almeida OliveiraFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
João Paulo Emiliano da SilvaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Rafael de Oliveira Calaça FariasFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Leonardo Prudêncio Coutinho de AlmeidaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Salomão Belfort Sparapan de MeloFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Sandra Taveiros de AraújoFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Raimundo Rodrigues de França-JúniorFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
José Emerson XavierFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil.
Carlos Alberto de Carvalho FragaFederal University of Alagoas, Arapiraca Campus, Center for Medical Sciences, Av. Manoel Severino Barbosa, Bom SucessoCEP 57309-005 Arapiraca, AL, Arapiraca, Brazil. carlos.fraga@arapiraca.ufal.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcitonin gene-related peptide (CGRP) and receptor activity modifier protein 1 (RAMP1) form a critical neuroimmunoendocrine axis in the modulation of neuroinflammation, pain, and tumor progression. CGRP, released by sensory and sympathetic fibers, is a potent vasodilator and nociceptive modulator; its action depends on the receptor composed of CALCRL and RAMP1. In the central nervous system, the activation of microglia and astrocytes and the induction of pathways such as NF-κB and MAPK culminate in the production of proinflammatory cytokines (TNF-α, IL-6), differing from systemic inflammation due to the presence of the blood-brain barrier and the glial microenvironment. Preclinical evidence demonstrates RAMP1 expression in neurons, glial cells, endothelium, and macrophages; CGRP/RAMP1 signaling promotes vascular permeability, cytokine release, and angiogenesis, potentially synergizing with VEGF. In animal models and cell cultures, genetic or pharmacological manipulations of the axis reduce tumor angiogenesis, pro-tumor immune infiltration, tumor growth, and nociceptive behavior. Given the clinical availability of CGRP antagonists and monoclonal antibodies, blocking the CGRP/RAMP1 axis is a promising translational strategy for modulating tumor progression and cancer pain. This review summarizes preclinical evidence on mechanisms and therapeutic feasibility. The article includes preclinical and clinical safety and biomarker studies.

Indexed as

Central Nervous SystemNeoplasmsNeuroinflammatory DiseasesPeripheral Nervous SystemReceptor Activity-Modifying Protein 1AnimalsCalcitonin Gene-Related PeptideDisease ProgressionHumansInflammationSignal TransductionCalcitonin Gene-Related PeptideReceptor Activity-Modifying Protein 1Calcitonin Gene-Related peptideCell proliferationRAMP, neuroinflammationTumor microenvironment

Identifiers

PMID41649670
PMCPMC13233887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.